The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.